Abstract:Abstract Background Glaucoma is a leading neurodegenerative disease affecting over 70 million individuals worldwide. Early pathological events of axonal degeneration and retinopathy in response to elevated intraocular pressure (IOP) are limited and not well-defined due to the lack of appropriate animal models that faithfully replicate all the phenotypes of primary open angle glaucoma (POAG), the most common form of glaucoma. Glucocorticoid (GC)-induced ocular hypertension (OHT) and its associated iatrogenic open-angle glaucoma share many features with POAG. Here, we characterized a novel mouse model of GC-induced OHT for glaucomatous neurodegeneration and further explored early pathological events of axonal degeneration in response to elevated IOP. Methods C57BL/6 J mice were periocularly injected with either vehicle or the potent GC, dexamethasone 21-acetate (Dex) once a week for 10 weeks. Glaucoma phenotypes including IOP, outflow facility, structural and functional loss of retinal ganglion cells (RGCs), optic nerve (ON) degeneration, gliosis, and anterograde axonal transport deficits were examined at various stages of OHT. Results Prolonged treatment with Dex leads to glaucoma in mice similar to POAG patients including IOP elevation due to reduced outflow facility and dysfunction of trabecular meshwork, progressive ON degeneration and structural and functional loss of RGCs. Lowering of IOP rescued Dex-induced ON degeneration and RGC loss, suggesting that glaucomatous neurodegeneration is IOP dependent. Also, Dex-induced neurodegeneration was associated with activation of astrocytes, axonal transport deficits, ON demyelination, mitochondrial accumulation and immune cell infiltration in the optic nerve head (ONH) region. Our studies further show that ON degeneration precedes structural and functional loss of RGCs in Dex-treated mice. Axonal damage and transport deficits initiate at the ONH and progress toward the distal end of ON and target regions in the brain (i.e. superior colliculus). Most of anterograde transport was preserved during initial stages of axonal degeneration (30% loss) and complete transport deficits were only observed at the ONH during later stages of severe axonal degeneration (50% loss). Conclusions These findings indicate that ON degeneration and transport deficits at the ONH precede RGC structural and functional loss and provide a new potential therapeutic window for rescuing neuronal loss and restoring health of damaged axons in glaucoma.

Transneuronal Degeneration in the Brain During Glaucoma

Protection of retinal ganglion cells in glaucoma: Current status and future

Glial Cell and Glaucomatous Optic Neuropathy

Regulatory mechanisms of retinal ganglion cell death in normal tension glaucoma and potential therapies

Glaucoma: the retina and beyond

Glaucoma: from pathogenic mechanisms to retinal glial cell response to damage

Impact of Glaucomatous Ganglion Cell Damage on Central Visual Function

Retinal Ganglion Cell Death in Glaucoma: Advances and Caveats

Regulated Necrosis in Glaucoma: Focus on Ferroptosis and Pyroptosis

Signalling pathways and cell death mechanisms in glaucoma: Insights into the molecular pathophysiology

Advances in Neuroprotection in Glaucoma: Pharmacological Strategies and Emerging Technologies

Synaptic Degeneration of Retinal Ganglion Cells in a Rat Ocular Hypertension Glaucoma Model

CNS axonal degeneration and transport deficits at the optic nerve head precede structural and functional loss of retinal ganglion cells in a mouse model of glaucoma

Therapeutic strategies for glaucoma and optic neuropathies

Progressive Ganglion Cell Degeneration Precedes Neuronal Loss in a Mouse Model of Glaucoma

The Molecular Mechanisms Involved in Axonal Degeneration and Retrograde Retinal Ganglion Cell Death

[Glaucoma--neurodegenerative disease]

Advances in Regeneration of Retinal Ganglion Cells and Optic Nerves

Towards Retinal Ganglion Cell Regeneration

Demyelination of the Optic Nerve: An Underlying Factor in Glaucoma?

Neuroprotection of Retinal Ganglion Cells Suppresses Microglia Activation in a Mouse Model of Glaucoma